Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 1, Issue 15

June 27 2017

In this Issue

EXCEPTIONAL CASE REPORTS
CLINICAL TRIALS AND OBSERVATIONS
HEMATOPOIESIS AND STEM CELLS
IMMUNOBIOLOGY
LYMPHOID NEOPLASIA
MYELOID NEOPLASIA
RED CELLS, IRON, AND ERYTHROPOIESIS
THROMBOSIS AND HEMOSTASIS
TRANSFUSION MEDICINE
TRANSPLANTATION
COMMENTARIES

EXCEPTIONAL CASE REPORTS

Graphical abstract for: Lymphadenopathy driven by TCR-V<sub>γ</sub>8V<sub>δ</sub>1 T-cell expansion in FAS-related autoimmune lymphoproliferative syndrome;

Lymphadenopathy driven by TCR-V_γ8V_δ1 T-cell expansion in FAS-related autoimmune lymphoproliferative syndrome
Clinical Trials & Observations

Stefano Vavassori,Jacob D. Galson,Johannes Trück,Anke van den Berg,Rienk Y. J. Tamminga,Aude Magerus-Chatinet,Olivier Pellé,Ulrike Camenisch Gross,Ewerton Marques Maggio,Seraina Prader,Lennart Opitz,Ursina Nüesch,Andrea Mauracher,Benjamin Volkmer,Oliver Speer,Luzia Suda,Benno Röthlisberger,Dieter Robert Zimmermann,Rouven Müller,Arjan Diepstra,Lydia Visser,Eugenia Haralambieva,Bénédicte Neven,Frédéric Rieux-Laucat,Jana Pachlopnik Schmid

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

Graphical abstract for: Novel <em>SF3B1</em> in-frame deletions result in aberrant RNA splicing in CLL patients;

Novel SF3B1 in-frame deletions result in aberrant RNA splicing in CLL patients
Clinical Trials & Observations

Anant A. Agrawal,Michael Seiler,Lindsey T. Brinton,Rose Mantel,Rosa Lapalombella,Jennifer A. Woyach,Amy J. Johnson,Ping Zhu,Markus Warmuth,Lihua Yu,John C. Byrd,Peter G. Smith,James S. Blachly,Silvia Buonamici

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

$Graphical abstract for: Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study;$

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study
Clinical Trials & Observations

Daniel J. DeAngelo,Wendy Stock,Anthony S. Stein,Andrei Shustov,Michaela Liedtke,Charles A. Schiffer,Erik Vandendries,Katherine Liau,Revathi Ananthakrishnan,Joseph Boni,A. Douglas Laird,Luke Fostvedt,Hagop M. Kantarjian,Anjali S. Advani

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

Graphical abstract for: Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens;

Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens
Clinical Trials & Observations

John-Paul Westwood,Mari Thomas,Ferras Alwan,Vickie McDonald,Sylvia Benjamin,William A. Lester,Gillian C. Lowe,Tina Dutt,Quentin A. Hill,Marie Scully

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

HEMATOPOIESIS AND STEM CELLS

High CD123 levels enhance proliferation in response to IL-3, but reduce chemotaxis by downregulating CXCR4 expression

Nicole L. Wittwer,Gabriela Brumatti,Ceilidh Marchant,Jarrod J. Sandow,Melanie K. Pudney,Mara Dottore,Richard J. D’Andrea,Angel F. Lopez,Paul G. Ekert,Hayley S. Ramshaw

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

Graphical abstract for: An aptamer-based targeted delivery of miR-26a protects mice against chemotherapy toxicity while suppressing tumor growth;

An aptamer-based targeted delivery of miR-26a protects mice against chemotherapy toxicity while suppressing tumor growth

Toshihiko Tanno,Peng Zhang,Christopher A. Lazarski,Yang Liu,Pan Zheng

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

IMMUNOBIOLOGY

Graphical abstract for: Substrate-bound CCL21 and ICAM1 combined with soluble IL-6 collectively augment the expansion of antigen-specific murine CD4<sup>+</sup> T cells;

Substrate-bound CCL21 and ICAM1 combined with soluble IL-6 collectively augment the expansion of antigen-specific murine CD4⁺ T cells

Shimrit Adutler-Lieber,Irina Zaretsky,Helena Sabany,Elena Kartvelishvily,Ofra Golani,Benjamin Geiger,Nir Friedman

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

LYMPHOID NEOPLASIA

A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies

Shu-Hui Liu,Yin Gu,Bernadette Pascual,Zhengming Yan,Max Hallin,Cathy Zhang,Conglin Fan,Wenlian Wang,Justine Lam,Mary E. Spilker,Rolla Yafawi,Eileen Blasi,Brett Simmons,Nanni Huser,Wei-Hsien Ho,Kevin Lindquist,Thomas-Toan Tran,Jyothirmayee Kudaravalli,Jing-Tyan Ma,Gretchen Jimenez,Ishita Barman,Colleen Brown,Sherman Michael Chin,Maria J. Costa,David Shelton,Tod Smeal,Valeria R. Fantin,Flavia Pernasetti

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

Clonality of HTLV-1–infected T cells as a risk indicator for development and progression of adult T-cell leukemia

Sanaz Firouzi,Amir Farmanbar,Kenta Nakai,Masako Iwanaga,Kaoru Uchimaru,Atae Utsunomiya,Yutaka Suzuki,Toshiki Watanabe

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

MYELOID NEOPLASIA

Graphical abstract for: Hmga2 collaborates with <em>JAK2</em>V617F in the development of myeloproliferative neoplasms;

Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms

Koki Ueda,Kazuhiko Ikeda,Takayuki Ikezoe,Kayo Harada-Shirado,Kazuei Ogawa,Yuko Hashimoto,Takahiro Sano,Hiroshi Ohkawara,Satoshi Kimura,Akiko Shichishima-Nakamura,Yuichi Nakamura,Yayoi Shikama,Tsutomu Mori,Philip J. Mason,Monica Bessler,Soji Morishita,Norio Komatsu,Kotaro Shide,Kazuya Shimoda,Shuhei Koide,Kazumasa Aoyama,Motohiko Oshima,Atsushi Iwama,Yasuchika Takeishi

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

Copy number alterations detected as clonal hematopoiesis of indeterminate potential

Koichi Takahashi,Feng Wang,Hagop Kantarjian,Xingzhi Song,Keyur Patel,Sattva Neelapu,Curtis Gumbs,Latasha Little,Samantha Tippen,Rebecca Thornton,Courtney D. DiNardo,Farhad Ravandi,Carlos Bueso-Ramos,Jianhua Zhang,Xifeng Wu,Guillermo Garcia-Manero,P. Andrew Futreal

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

A specialized pathway for erythroid iron delivery through lysosomal trafficking of transferrin receptor 2

Shadi Khalil,Maja Holy,Stephen Grado,Robert Fleming,Ryo Kurita,Yukio Nakamura,Adam Goldfarb

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

THROMBOSIS AND HEMOSTASIS

Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: mode of its action

Shiva Keshava,Jagan Sundaram,Anuradha Rajulapati,Charles T. Esmon,Usha R. Pendurthi,L. Vijaya Mohan Rao

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Graphical abstract for: Variable phenotypic penetrance of thrombosis in adult mice after tissue-selective and temporally controlled Thbd gene inactivation;

Variable phenotypic penetrance of thrombosis in adult mice after tissue-selective and temporally controlled Thbd gene inactivation

Thijs E. van Mens,Hai-Po H. Liang,Sreemanti Basu,Irene Hernandez,Mark Zogg,Jennifer May,Min Zhan,Qiuhui Yang,Jamie Foeckler,Shawn Kalloway,Rashmi Sood,Caren Sue Karlson,Hartmut Weiler

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Graphical abstract for: Genetic variants in <em>ADAMTS13</em> as well as smoking are major determinants of plasma ADAMTS13 levels;

Genetic variants in ADAMTS13 as well as smoking are major determinants of plasma ADAMTS13 levels

Qianyi Ma,Paula M. Jacobi,Brian T. Emmer,Colin A. Kretz,Ayse Bilge Ozel,Beth McGee,Chava Kimchi-Sarfaty,David Ginsburg,Jun Z. Li,Karl C. Desch

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

12-HETrE inhibits platelet reactivity and thrombosis in part through the prostacyclin receptor

Benjamin E. Tourdot,Reheman Adili,Zitha R. Isingizwe,Meral Ebrahem,J. Cody Freedman,Theodore R. Holman,Michael Holinstat

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

Graphical abstract for: Multiplexed targeted proteomic assay to assess coagulation factor concentrations and thrombosis-associated cancer;

Multiplexed targeted proteomic assay to assess coagulation factor concentrations and thrombosis-associated cancer

Yassene Mohammed,Bart J. van Vlijmen,Juncong Yang,Andrew J. Percy,Magnus Palmblad,Christoph H. Borchers,Frits R. Rosendaal

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

TRANSFUSION MEDICINE

Graphical abstract for: Ethnicity, sex, and age are determinants of red blood cell storage and stress hemolysis: results of the REDS-III RBC-Omics study;

Ethnicity, sex, and age are determinants of red blood cell storage and stress hemolysis: results of the REDS-III RBC-Omics study

Tamir Kanias,for the National Heart, Lung, and Blood Institute Recipient Epidemiology Donor Evaluation Study III (REDS-III) Program,Marion C. Lanteri,for the National Heart, Lung, and Blood Institute Recipient Epidemiology Donor Evaluation Study III (REDS-III) Program,Grier P. Page,for the National Heart, Lung, and Blood Institute Recipient Epidemiology Donor Evaluation Study III (REDS-III) Program,Yuelong Guo,for the National Heart, Lung, and Blood Institute Recipient Epidemiology Donor Evaluation Study III (REDS-III) Program,Stacy M. Endres,for the National Heart, Lung, and Blood Institute Recipient Epidemiology Donor Evaluation Study III (REDS-III) Program,Mars Stone,for the National Heart, Lung, and Blood Institute Recipient Epidemiology Donor Evaluation Study III (REDS-III) Program,Sheila Keating,for the National Heart, Lung, and Blood Institute Recipient Epidemiology Donor Evaluation Study III (REDS-III) Program,Alan E. Mast,for the National Heart, Lung, and Blood Institute Recipient Epidemiology Donor Evaluation Study III (REDS-III) Program,Ritchard G. Cable,for the National Heart, Lung, and Blood Institute Recipient Epidemiology Donor Evaluation Study III (REDS-III) Program,Darrell J. Triulzi,for the National Heart, Lung, and Blood Institute Recipient Epidemiology Donor Evaluation Study III (REDS-III) Program,Joseph E. Kiss,for the National Heart, Lung, and Blood Institute Recipient Epidemiology Donor Evaluation Study III (REDS-III) Program,Edward L. Murphy,for the National Heart, Lung, and Blood Institute Recipient Epidemiology Donor Evaluation Study III (REDS-III) Program,Steve Kleinman,for the National Heart, Lung, and Blood Institute Recipient Epidemiology Donor Evaluation Study III (REDS-III) Program,Michael P. Busch,for the National Heart, Lung, and Blood Institute Recipient Epidemiology Donor Evaluation Study III (REDS-III) Program,Mark T. Gladwin,for the National Heart, Lung, and Blood Institute Recipient Epidemiology Donor Evaluation Study III (REDS-III) Program

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

TRANSPLANTATION

Graphical abstract for: Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT;

Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT

Christine M. Ho,Philip L. McCarthy,Paul K. Wallace,Yali Zhang,Ahmad Fora,Patrick Mellors,Joseph D. Tario,Benjamin L. S. McCarthy,George L. Chen,Sarah A. Holstein,Sophia R. Balderman,Xuefang Cao,Bruno Paiva,Theresa Hahn

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

Graphical abstract for: Single umbilical cord blood with or without CD34<sup>+</sup> cells from a third-party donor in adults with leukemia;

Single umbilical cord blood with or without CD34⁺ cells from a third-party donor in adults with leukemia
Clinical Trials & Observations

Jaime Sanz,on behalf of Grupo Español de Trasplante Hematopoyético (GETH),Mi Kwon,on behalf of Grupo Español de Trasplante Hematopoyético (GETH),Guiomar Bautista,on behalf of Grupo Español de Trasplante Hematopoyético (GETH),Miguel A. Sanz,on behalf of Grupo Español de Trasplante Hematopoyético (GETH),Pascual Balsalobre,on behalf of Grupo Español de Trasplante Hematopoyético (GETH),José Luis Piñana,on behalf of Grupo Español de Trasplante Hematopoyético (GETH),Carlos Solano,on behalf of Grupo Español de Trasplante Hematopoyético (GETH),Rafael Duarte,on behalf of Grupo Español de Trasplante Hematopoyético (GETH),Christelle Ferrá,on behalf of Grupo Español de Trasplante Hematopoyético (GETH),Ignacio Lorenzo,on behalf of Grupo Español de Trasplante Hematopoyético (GETH),Carmen Martín,on behalf of Grupo Español de Trasplante Hematopoyético (GETH),Pere Barba,on behalf of Grupo Español de Trasplante Hematopoyético (GETH),María Jesús Pascual,on behalf of Grupo Español de Trasplante Hematopoyético (GETH),Rodrigo Martino,on behalf of Grupo Español de Trasplante Hematopoyético (GETH),Jorge Gayoso,on behalf of Grupo Español de Trasplante Hematopoyético (GETH),Ismael Buño,on behalf of Grupo Español de Trasplante Hematopoyético (GETH),Carmen Regidor,on behalf of Grupo Español de Trasplante Hematopoyético (GETH),Almudena de la Iglesia,on behalf of Grupo Español de Trasplante Hematopoyético (GETH),Juan Montoro,on behalf of Grupo Español de Trasplante Hematopoyético (GETH),José Luis Díez-Martín,on behalf of Grupo Español de Trasplante Hematopoyético (GETH),Guillermo F. Sanz,on behalf of Grupo Español de Trasplante Hematopoyético (GETH),Rafael Cabrera,on behalf of Grupo Español de Trasplante Hematopoyético (GETH)

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Supplemental data

COMMENTARIES

Ovarian vein thrombus: to treat or not to treat?
Clinical Trials & Observations

Trisha Plastini,David Henry,Katie Dunleavy

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Implications of the US Food and Drug Administration draft guidance for mitigating septic reactions from platelet transfusions

Bruce S. Sachais,Sarai Paradiso,Donna Strauss,Beth H. Shaz

View Articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text

Cover Image

Cover Image

COVER FIGURE
Model of evolution from clonal hematopoiesis of indeterminate potential (CHIP) to therapy-related myeloid neoplasms. A CHIP clone with a DNMT3A mutation acquired deletion 7, and then 2 subclones acquired a PTPN11 mutation and trisomy 22, an NRAS mutation. See the article by Takahashi et al.
Front Matter
Editorial Board

All Issues

Advertisement intended for health care professionals

Email alerts

Continuous Publishing Alert

New Journal Content Alert

Close Modal

Latest
Most Read
Most Cited

MRD assessment by flow cytometry in B-ALL made easier

Targeting the lectin pathway in TA-TMA

Give megs a break: minor DNA stress, platelets in excess

Chihara D, Steiner RE, Nair R, et al. Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas. Blood Adv. 2025;9(7):1485-1491.

Casulo C, Dixon JG, Ou F-S, et al. Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. Blood Adv. 2021;5(6):1737-1745.

Advertisement intended for health care professionals

Table of Contents

EXCEPTIONAL CASE REPORTS

Lymphadenopathy driven by TCR-V_γ8V_δ1 T-cell expansion in FAS-related autoimmune lymphoproliferative syndrome
Clinical Trials & Observations

Novel SF3B1 in-frame deletions result in aberrant RNA splicing in CLL patients
Clinical Trials & Observations

CLINICAL TRIALS AND OBSERVATIONS

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study
Clinical Trials & Observations

Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens
Clinical Trials & Observations

HEMATOPOIESIS AND STEM CELLS

High CD123 levels enhance proliferation in response to IL-3, but reduce chemotaxis by downregulating CXCR4 expression

An aptamer-based targeted delivery of miR-26a protects mice against chemotherapy toxicity while suppressing tumor growth

IMMUNOBIOLOGY

Substrate-bound CCL21 and ICAM1 combined with soluble IL-6 collectively augment the expansion of antigen-specific murine CD4⁺ T cells

LYMPHOID NEOPLASIA

A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies

Clonality of HTLV-1–infected T cells as a risk indicator for development and progression of adult T-cell leukemia

MYELOID NEOPLASIA

Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms

Copy number alterations detected as clonal hematopoiesis of indeterminate potential

RED CELLS, IRON, AND ERYTHROPOIESIS

A specialized pathway for erythroid iron delivery through lysosomal trafficking of transferrin receptor 2

THROMBOSIS AND HEMOSTASIS

Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: mode of its action

Variable phenotypic penetrance of thrombosis in adult mice after tissue-selective and temporally controlled Thbd gene inactivation

Genetic variants in ADAMTS13 as well as smoking are major determinants of plasma ADAMTS13 levels

12-HETrE inhibits platelet reactivity and thrombosis in part through the prostacyclin receptor

Multiplexed targeted proteomic assay to assess coagulation factor concentrations and thrombosis-associated cancer

TRANSFUSION MEDICINE

Ethnicity, sex, and age are determinants of red blood cell storage and stress hemolysis: results of the REDS-III RBC-Omics study

TRANSPLANTATION

Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT

Single umbilical cord blood with or without CD34⁺ cells from a third-party donor in adults with leukemia
Clinical Trials & Observations

COMMENTARIES

Ovarian vein thrombus: to treat or not to treat?
Clinical Trials & Observations

Implications of the US Food and Drug Administration draft guidance for mitigating septic reactions from platelet transfusions

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

EXCEPTIONAL CASE REPORTS

Lymphadenopathy driven by TCR-Vγ8Vδ1 T-cell expansion in FAS-related autoimmune lymphoproliferative syndrome Clinical Trials & Observations

Novel SF3B1 in-frame deletions result in aberrant RNA splicing in CLL patients Clinical Trials & Observations

CLINICAL TRIALS AND OBSERVATIONS

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study Clinical Trials & Observations

Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens Clinical Trials & Observations

HEMATOPOIESIS AND STEM CELLS

IMMUNOBIOLOGY

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

RED CELLS, IRON, AND ERYTHROPOIESIS

THROMBOSIS AND HEMOSTASIS

TRANSFUSION MEDICINE

TRANSPLANTATION

Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia Clinical Trials & Observations

COMMENTARIES

Ovarian vein thrombus: to treat or not to treat? Clinical Trials & Observations

Cover Image

Email alerts

ASH Publications

American Society of Hematology

Lymphadenopathy driven by TCR-V_γ8V_δ1 T-cell expansion in FAS-related autoimmune lymphoproliferative syndrome
Clinical Trials & Observations

Novel SF3B1 in-frame deletions result in aberrant RNA splicing in CLL patients
Clinical Trials & Observations

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study
Clinical Trials & Observations

Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens
Clinical Trials & Observations

Single umbilical cord blood with or without CD34⁺ cells from a third-party donor in adults with leukemia
Clinical Trials & Observations

Ovarian vein thrombus: to treat or not to treat?
Clinical Trials & Observations